Advertisement

Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis

Published:November 11, 2019DOI:https://doi.org/10.1016/j.jhep.2019.10.026

      Highlights

      • The proline biosynthesis pathway is altered in HCC tumors.
      • PYCR1 and ALDH18A1 are upregulated in HCC tumors.
      • Inhibition of PYCR1 or ALDH18A1 leads to reduced tumor burden.
      • PYCR1 and ALDH18A1 are independent predictors of HCC patient survival.
      • PYCR1 and ALDH18A1 may be novel therapeutic targets in liver cancer.

      Background & Aim

      Under the regulation of various oncogenic pathways, cancer cells undergo adaptive metabolic programming to maintain specific metabolic states that support their uncontrolled proliferation. As it has been difficult to directly and effectively inhibit oncogenic signaling cascades with pharmaceutical compounds, focusing on the downstream metabolic pathways that enable indefinite growth may provide therapeutic opportunities. Thus, we sought to characterize metabolic changes in hepatocellular carcinoma (HCC) development and identify metabolic targets required for tumorigenesis.

      Methods

      We compared gene expression profiles of Morris Hepatoma (MH3924a) and DEN (diethylnitrosamine)-induced HCC models to those of liver tissues from normal and rapidly regenerating liver models, and performed gain- and loss-of-function studies of the identified gene targets for their roles in cancer cell proliferation in vitro and in vivo.

      Results

      The proline biosynthetic enzyme PYCR1 (pyrroline-5-carboxylate reductase 1) was identified as one of the most upregulated genes in the HCC models. Knockdown of PYCR1 potently reduced cell proliferation of multiple HCC cell lines in vitro and tumor growth in vivo. Conversely, overexpression of PYCR1 enhanced the proliferation of the HCC cell lines. Importantly, PYCR1 expression was not elevated in the regenerating liver, and KD or overexpression of PYCR1 had no effect on proliferation of non-cancerous cells. Besides PYCR1, we found that additional proline biosynthetic enzymes, such as ALDH18A1, were upregulated in HCC models and also regulated HCC cell proliferation. Clinical data demonstrated that PYCR1 expression was increased in HCC, correlated with tumor grade, and was an independent predictor of clinical outcome.

      Conclusion

      Enhanced expression of proline biosynthetic enzymes promotes HCC cell proliferation. Inhibition of PYCR1 or ALDH18A1 may be a novel therapeutic strategy to target HCC.

      Lay summary

      Even with the recently approved immunotherapies against liver cancer, currently available medications show limited clinical benefits or efficacy in the majority of patients. As such, it remains a top priority to discover new targets for effective liver cancer treatment. Here, we identify a critical role for the proline biosynthetic pathway in liver cancer development, and demonstrate that targeting key proteins in the pathway, namely PYCR1 and ALDH18A1, may be a novel therapeutic strategy for liver cancer.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • El-Serag H.B.
        Hepatocellular carcinoma.
        N Engl J Med. 2011; 365: 1118-1127
        • Llovet J.M.
        • Bruix J.
        Molecular targeted therapies in hepatocellular carcinoma.
        Hepatology. 2008; 48: 1312-1327
        • Gyawali B.
        • Prasad V.
        Health policy: me-too drugs with limited benefits - the tale of regorafenib for HCC.
        Nat Rev Clin Oncol. 2017; 14: 653-654
        • El-Khoueiry A.B.
        • Sangro B.
        • Yau T.
        • Crocenzi T.S.
        • Kudo M.
        • Hsu C.
        • et al.
        Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
        Lancet. 2017; 389: 2492-2502
        • Al-Salama Z.T.
        • Syed Y.Y.
        • Scott L.J.
        Lenvatinib: a Review in hepatocellular carcinoma.
        Drugs. 2019; 79: 665-674
        • Deeks E.D.
        Cabozantinib: a review in advanced hepatocellular carcinoma.
        Target Oncol. 2019; 14: 107-113
        • Zhu A.X.
        • Finn R.S.
        • Edeline J.
        • Cattan S.
        • Ogasawara S.
        • Palmer D.
        • et al.
        Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
        Lancet Oncol. 2018; 19: 940-952
        • Boroughs L.K.
        • DeBerardinis R.J.
        Metabolic pathways promoting cancer cell survival and growth.
        Nat Cell Biol. 2015; 17: 351-359
        • Ward P.S.
        • Thompson C.B.
        Metabolic reprogramming: a cancer hallmark even warburg did not anticipate.
        Cancer Cell. 2012; 21: 297-308
        • Pavlova N.N.
        • Thompson C.B.
        The emerging hallmarks of cancer metabolism.
        Cell Metab. 2016; 23: 27-47
        • Locasale J.W.
        • Grassian A.R.
        • Melman T.
        • Lyssiotis C.A.
        • Mattaini K.R.
        • Bass A.J.
        • et al.
        Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis.
        Nat Genet. 2011; 43: 869-874
        • Possemato R.
        • Marks K.M.
        • Shaul Y.D.
        • Pacold M.E.
        • Kim D.
        • Birsoy K.
        • et al.
        Functional genomics reveal that the serine synthesis pathway is essential in breast cancer.
        Nature. 2011; 476: 346-350
        • Pacold M.E.
        • Brimacombe K.R.
        • Chan S.H.
        • Rohde J.M.
        • Lewis C.A.
        • Swier L.J.
        • et al.
        A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate.
        Nat Chem Biol. 2016; 12: 452-458
        • Ericksen R.E.
        • Lim S.L.
        • McDonnell E.
        • Shuen W.H.
        • Vadiveloo M.
        • White P.J.
        • et al.
        Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression.
        Cell Metab. 2019; 29: 1151-1165.e6
        • Sarbassov D.D.
        • Guertin D.A.
        • Ali S.M.
        • Sabatini D.M.
        Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.
        Science. 2005; 307: 1098-1101
        • Wiederschain D.
        • Wee S.
        • Chen L.
        • Loo A.
        • Yang G.
        • Huang A.
        • et al.
        Single-vector inducible lentiviral RNAi system for oncology target validation.
        Cell Cycle. 2009; 8: 498-504
        • Yang W.
        • Guo X.
        • Thein S.
        • Xu F.
        • Sugii S.
        • Baas P.W.
        • et al.
        Regulation of adipogenesis by cytoskeleton remodelling is facilitated by acetyltransferase MEC-17-dependent acetylation of alpha-tubulin.
        Biochem J. 2013; 449: 605-612
        • Mitchell C.
        • Willenbring H.
        A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice.
        Nat Protoc. 2008; 3: 1167-1170
        • Herwig R.
        • Hardt C.
        • Lienhard M.
        • Kamburov A.
        Analyzing and interpreting genome data at the network level with ConsensusPathDB.
        Nat Protoc. 2016; 11: 1889-1907
        • Subramanian A.
        • Tamayo P.
        • Mootha V.K.
        • Mukherjee S.
        • Ebert B.L.
        • Gillette M.A.
        • et al.
        Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
        Proc Natl Acad Sci U S A. 2005; 102: 15545-15550
        • Mootha V.K.
        • Lindgren C.M.
        • Eriksson K.F.
        • Subramanian A.
        • Sihag S.
        • Lehar J.
        • et al.
        PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes.
        Nat Genet. 2003; 34: 267-273
        • Enane F.O.
        • Shuen W.H.
        • Gu X.
        • Quteba E.
        • Przychodzen B.
        • Makishima H.
        • et al.
        GATA4 loss of function in liver cancer impedes precursor to hepatocyte transition.
        J Clin Invest. 2017; 127: 3527-3542
        • Uhlen M.
        • Fagerberg L.
        • Hallstrom B.M.
        • Lindskog C.
        • Oksvold P.
        • Mardinoglu A.
        • et al.
        Proteomics. Tissue-based map of the human proteome.
        Science. 2015; 347: 1260419
        • Uhlen M.
        • Oksvold P.
        • Fagerberg L.
        • Lundberg E.
        • Jonasson K.
        • Forsberg M.
        • et al.
        Towards a knowledge-based human protein atlas.
        Nat Biotechnol. 2010; 28: 1248-1250
        • Uhlen M.
        • Bjorling E.
        • Agaton C.
        • Szigyarto C.A.
        • Amini B.
        • Andersen E.
        • et al.
        A human protein atlas for normal and cancer tissues based on antibody proteomics.
        Mol Cell Proteomics. 2005; 4: 1920-1932
        • Ponten F.
        • Jirstrom K.
        • Uhlen M.
        The human protein atlas–a tool for pathology.
        J Pathol. 2008; 216: 387-393
        • Ding J.
        • Kuo M.L.
        • Su L.
        • Xue L.
        • Luh F.
        • Zhang H.
        • et al.
        Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
        Carcinogenesis. 2017; 38: 519-531
        • Zeng T.
        • Zhu L.
        • Liao M.
        • Zhuo W.
        • Yang S.
        • Wu W.
        • et al.
        Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer.
        Med Oncol. 2017; 34: 27
        • Phang J.M.
        The regulatory functions of proline and pyrroline-5-carboxylic acid.
        Curr Top Cell Regul. 1985; 25: 91-132
        • Liu Y.
        • Borchert G.L.
        • Donald S.P.
        • Diwan B.A.
        • Anver M.
        • Phang J.M.
        Proline oxidase functions as a mitochondrial tumor suppressor in human cancers.
        Cancer Res. 2009; 69: 6414-6422
        • Liu W.
        • Glunde K.
        • Bhujwalla Z.M.
        • Raman V.
        • Sharma A.
        • Phang J.M.
        Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments.
        Cancer Res. 2012; 72: 3677-3686
        • Phang J.M.
        • Liu W.
        • Hancock C.
        • Christian K.J.
        The proline regulatory axis and cancer.
        Front Oncol. 2012; 2: 60
        • Phang J.M.
        • Liu W.
        • Hancock C.N.
        • Fischer J.W.
        Proline metabolism and cancer: emerging links to glutamine and collagen.
        Curr Opin Clin Nutr Metab Care. 2015; 18: 71-77
        • Liu W.
        • Hancock C.N.
        • Fischer J.W.
        • Harman M.
        • Phang J.M.
        Proline biosynthesis augments tumor cell growth and aerobic glycolysis: involvement of pyridine nucleotides.
        Sci Rep. 2015; 5: 17206
        • Canto C.
        • Menzies K.J.
        • Auwerx J.
        NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus.
        Cell Metab. 2015; 22: 31-53
        • Donald S.P.
        • Sun X.Y.
        • Hu C.A.
        • Yu J.
        • Mei J.M.
        • Valle D.
        • et al.
        Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species.
        Cancer Res. 2001; 61: 1810-1815
        • Zarse K.
        • Schmeisser S.
        • Groth M.
        • Priebe S.
        • Beuster G.
        • Kuhlow D.
        • et al.
        Impaired insulin/IGF1 signaling extends life span by promoting mitochondrial L-proline catabolism to induce a transient ROS signal.
        Cell Metab. 2012; 15: 451-465
        • Natarajan S.K.
        • Zhu W.
        • Liang X.
        • Zhang L.
        • Demers A.J.
        • Zimmerman M.C.
        • et al.
        Proline dehydrogenase is essential for proline protection against hydrogen peroxide-induced cell death.
        Free Radic Biol Med. 2012; 53: 1181-1191
        • Krishnan N.
        • Dickman M.B.
        • Becker D.F.
        Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress.
        Free Radic Biol Med. 2008; 44: 671-681
        • Wise D.R.
        • Thompson C.B.
        Glutamine addiction: a new therapeutic target in cancer.
        Trends Biochem Sci. 2010; 35: 427-433
        • Ahn C.S.
        • Metallo C.M.
        Mitochondria as biosynthetic factories for cancer proliferation.
        Cancer Metab. 2015; 3: 1
        • Loayza-Puch F.
        • Rooijers K.
        • Buil L.C.
        • Zijlstra J.
        • Oude Vrielink J.F.
        • Lopes R.
        • et al.
        Tumour-specific proline vulnerability uncovered by differential ribosome codon reading.
        Nature. 2016; 530: 490-494
        • DeClerck Y.A.
        Desmoplasia: a response or a niche?.
        Cancer Discov. 2012; 2: 772-774
        • Nilsson R.
        • Jain M.
        • Madhusudhan N.
        • Sheppard N.G.
        • Strittmatter L.
        • Kampf C.
        • et al.
        Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer.
        Nat Commun. 2014; 5: 3128